Trade AbCellera Biologics Inc. - ABCL CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 4.7 |
Open* | 4.51 |
1-Year Change* | -64.74% |
Day's Range* | 4.51 - 4.82 |
52 wk Range | 3.87-14.15 |
Average Volume (10 days) | 1.37M |
Average Volume (3 months) | 33.06M |
Market Cap | 1.26B |
P/E Ratio | -100.00K |
Shares Outstanding | 290.17M |
Revenue | 50.39M |
EPS | -0.45 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Feb 19, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 4.81 | 0.21 | 4.57% | 4.60 | 4.83 | 4.49 |
Nov 30, 2023 | 4.70 | -0.06 | -1.26% | 4.76 | 4.84 | 4.54 |
Nov 29, 2023 | 4.74 | 0.03 | 0.64% | 4.71 | 5.00 | 4.67 |
Nov 28, 2023 | 4.70 | 0.22 | 4.91% | 4.48 | 4.76 | 4.36 |
Nov 27, 2023 | 4.50 | 0.17 | 3.93% | 4.33 | 4.52 | 4.25 |
Nov 24, 2023 | 4.40 | 0.05 | 1.15% | 4.35 | 4.45 | 4.35 |
Nov 22, 2023 | 4.40 | 0.02 | 0.46% | 4.38 | 4.43 | 4.31 |
Nov 21, 2023 | 4.31 | -0.16 | -3.58% | 4.47 | 4.52 | 4.29 |
Nov 20, 2023 | 4.57 | 0.18 | 4.10% | 4.39 | 4.66 | 4.31 |
Nov 17, 2023 | 4.43 | 0.11 | 2.55% | 4.32 | 4.45 | 4.27 |
Nov 16, 2023 | 4.36 | -0.10 | -2.24% | 4.46 | 4.46 | 4.22 |
Nov 15, 2023 | 4.50 | 0.16 | 3.69% | 4.34 | 4.63 | 4.26 |
Nov 14, 2023 | 4.30 | 0.15 | 3.61% | 4.15 | 4.34 | 4.10 |
Nov 13, 2023 | 3.96 | -0.02 | -0.50% | 3.98 | 4.00 | 3.91 |
Nov 10, 2023 | 4.01 | -0.02 | -0.50% | 4.03 | 4.03 | 3.87 |
Nov 9, 2023 | 4.02 | -0.08 | -1.95% | 4.10 | 4.24 | 4.02 |
Nov 8, 2023 | 4.16 | -0.15 | -3.48% | 4.31 | 4.35 | 4.09 |
Nov 7, 2023 | 4.36 | -0.04 | -0.91% | 4.40 | 4.50 | 4.25 |
Nov 6, 2023 | 4.44 | -0.16 | -3.48% | 4.60 | 4.76 | 4.41 |
Nov 3, 2023 | 4.67 | 0.71 | 17.93% | 3.96 | 4.73 | 3.96 |
AbCellera Biologics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, February 19, 2024 | ||
Time (UTC) 21:00 | Country US
| Event Q4 2023 Abcellera Biologics Inc Earnings Release Q4 2023 Abcellera Biologics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 485.424 | 375.203 | 233.155 | 11.6115 | 8.83056 |
Revenue | 485.424 | 375.203 | 233.155 | 11.6115 | 8.83056 |
Total Operating Expense | 268.913 | 170.79 | 80.824 | 15.7285 | 9.58317 |
Selling/General/Admin. Expenses, Total | 66.755 | 48.761 | 15.752 | 4.01153 | 2.86219 |
Research & Development | 107.879 | 62.062 | 29.393 | 10.1129 | 5.80252 |
Depreciation / Amortization | 27.843 | 14.451 | 4.836 | 1.60408 | 0.91846 |
Operating Income | 216.511 | 204.413 | 152.331 | -4.11701 | -0.75261 |
Interest Income (Expense), Net Non-Operating | 12.034 | -2.75 | -2.818 | 0.13181 | -0.5325 |
Other, Net | 10.554 | 17.486 | 8.32 | 1.7745 | 1.59397 |
Net Income Before Taxes | 239.099 | 219.149 | 157.833 | -2.2107 | 0.30885 |
Net Income After Taxes | 158.519 | 153.464 | 118.918 | -2.2107 | 0.30885 |
Net Income Before Extra. Items | 158.519 | 153.464 | 118.918 | -2.2107 | 0.30885 |
Net Income | 158.519 | 153.464 | 118.918 | -2.2107 | 0.30885 |
Total Adjustments to Net Income | 0 | -0.01695 | |||
Income Available to Common Excl. Extra. Items | 158.519 | 153.464 | 118.918 | -2.2107 | 0.29191 |
Income Available to Common Incl. Extra. Items | 158.519 | 153.464 | 118.918 | -2.2107 | 0.29191 |
Diluted Net Income | 158.519 | 153.464 | 118.918 | -2.2107 | 0.29191 |
Diluted Weighted Average Shares | 314.827 | 318.294 | 269.498 | 265.565 | 265.565 |
Diluted EPS Excluding Extraordinary Items | 0.50351 | 0.48215 | 0.44126 | -0.00832 | 0.0011 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | 0.50351 | 0.48215 | 0.4516 | -0.00832 | 0.0011 |
Unusual Expense (Income) | 3.7 | ||||
Other Operating Expenses, Total | 66.436 | 45.516 | 27.143 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 10.056 | 12.192 | 21.545 | 101.383 | 45.917 |
Revenue | 10.056 | 12.192 | 21.545 | 101.383 | 45.917 |
Total Operating Expense | 61.445 | 77.066 | 59.323 | 63.648 | 54.313 |
Selling/General/Admin. Expenses, Total | 19.362 | 18.905 | 15.706 | 16.881 | 17.532 |
Research & Development | 36.473 | 52.647 | 28.245 | 26.582 | 26.685 |
Depreciation / Amortization | 5.61 | 5.514 | 13.818 | 5.15 | 4.886 |
Other Operating Expenses, Total | 0 | 0 | 1.554 | 15.035 | 5.21 |
Operating Income | -51.389 | -64.874 | -37.778 | 37.735 | -8.396 |
Interest Income (Expense), Net Non-Operating | 10.779 | 9.759 | 12.034 | ||
Other, Net | 2.606 | 6.967 | -5.668 | 8.852 | 1.51 |
Net Income Before Taxes | -38.004 | -48.148 | -31.412 | 46.587 | -6.886 |
Net Income After Taxes | -30.528 | -40.11 | -29.893 | 26.624 | -6.785 |
Net Income Before Extra. Items | -30.528 | -40.11 | -29.893 | 26.624 | -6.785 |
Net Income | -30.528 | -40.11 | -29.893 | 26.624 | -6.785 |
Income Available to Common Excl. Extra. Items | -30.528 | -40.11 | -29.893 | 26.624 | -6.785 |
Income Available to Common Incl. Extra. Items | -30.528 | -40.11 | -29.893 | 26.624 | -6.785 |
Diluted Net Income | -30.528 | -40.11 | -29.893 | 26.624 | -6.785 |
Diluted Weighted Average Shares | 288.906 | 287.767 | 286.308 | 315.818 | 284.687 |
Diluted EPS Excluding Extraordinary Items | -0.10567 | -0.13938 | -0.10441 | 0.0843 | -0.02383 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.10567 | -0.13938 | -0.10441 | 0.0843 | -0.02383 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1025.49 | 929.8 | 813.325 | 12.6403 | 15.1622 |
Cash and Short Term Investments | 886.485 | 722.977 | 595.019 | 9.67689 | 11.0399 |
Cash & Equivalents | 386.535 | 476.142 | 594.116 | 7.55292 | 10.4443 |
Short Term Investments | 499.95 | 246.835 | 0.903 | 2.12397 | 0.59558 |
Total Receivables, Net | 103.41 | 174.858 | 212.336 | 2.25386 | 3.57203 |
Accounts Receivable - Trade, Net | 38.593 | 160.576 | 212.336 | 1.15256 | 0.80888 |
Prepaid Expenses | 9.064 | 5.293 | 0.70959 | 0.55034 | |
Total Assets | 1540.91 | 1318.57 | 1005.54 | 23.4881 | 21.4922 |
Property/Plant/Equipment, Total - Net | 217.255 | 111.616 | 17.923 | 8.47994 | 6.32994 |
Property/Plant/Equipment, Total - Gross | 235.73 | 121.442 | 23.509 | 11.6369 | 7.88282 |
Accumulated Depreciation, Total | -18.475 | -9.826 | -5.586 | -3.15696 | -1.55288 |
Note Receivable - Long Term | 0 | 1.78302 | 0 | ||
Other Long Term Assets, Total | 46.331 | 30.642 | 8.388 | 0.58478 | 0 |
Total Current Liabilities | 118.32 | 120.676 | 103.49 | 7.89486 | 6.43338 |
Payable/Accrued | 14.828 | 14.924 | 7.13 | 1.64337 | 1.51822 |
Accrued Expenses | 12.037 | 3.652 | 0.675 | 0.41914 | 0 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0.38725 | 0 |
Current Port. of LT Debt/Capital Leases | 0.19 | 2.07973 | 2.53135 | ||
Other Current Liabilities, Total | 91.455 | 102.1 | 95.495 | 3.36537 | 2.38381 |
Total Liabilities | 307.63 | 292.836 | 175.028 | 13.2359 | 9.88297 |
Total Long Term Debt | 0 | 0 | 2.198 | 1.36314 | 0.91122 |
Long Term Debt | 2.198 | 1.36314 | 0.91122 | ||
Other Liabilities, Total | 156.132 | 134.79 | 43.179 | 3.97792 | 2.53837 |
Total Equity | 1233.28 | 1025.73 | 830.508 | 10.2521 | 11.6092 |
Preferred Stock - Non Redeemable, Net | 0 | 7.54585 | 7.55701 | ||
Common Stock | 734.365 | 722.43 | 710.387 | 5.12175 | 5.07369 |
Additional Paid-In Capital | 74.118 | 35.357 | 5.919 | 2.30018 | 1.48344 |
Retained Earnings (Accumulated Deficit) | 426.185 | 267.666 | 114.202 | -4.71563 | -2.50494 |
Total Liabilities & Shareholders’ Equity | 1540.91 | 1318.57 | 1005.54 | 23.4881 | 21.4922 |
Total Common Shares Outstanding | 286.852 | 283.257 | 269.498 | 265.565 | 265.565 |
Other Current Assets, Total | 25 | 25 | 5.97 | ||
Goodwill, Net | 47.806 | 47.806 | 31.5 | ||
Intangibles, Net | 131.502 | 148.392 | 115.153 | ||
Long Term Investments | 72.522 | 50.313 | 19.247 | ||
Deferred Income Tax | 33.178 | 37.37 | 26.161 | ||
Total Inventory | 1.532 | 1.672 | |||
Other Equity, Total | -1.391 | 0.28 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 919.518 | 930.735 | 940.653 | 1025.49 | 1045.67 |
Cash and Short Term Investments | 785.84 | 795.694 | 796.495 | 886.485 | 868.206 |
Cash & Equivalents | 172.422 | 179.747 | 193.017 | 386.535 | 371.973 |
Total Receivables, Net | 75.483 | 86.233 | 99.569 | 103.41 | 105.964 |
Accounts Receivable - Trade, Net | 37.446 | 45.678 | 20.003 | 38.593 | 105.964 |
Total Inventory | 1.194 | 1.447 | 1.447 | 1.532 | |
Prepaid Expenses | 32.001 | 22.361 | 18.142 | 9.064 | |
Total Assets | 1512.19 | 1537.17 | 1497.92 | 1540.91 | 1552.41 |
Property/Plant/Equipment, Total - Net | 277.209 | 259.64 | 233.187 | 217.255 | 200.602 |
Property/Plant/Equipment, Total - Gross | 304.239 | 283.847 | 254.52 | 235.73 | 216.339 |
Accumulated Depreciation, Total | -27.03 | -24.207 | -21.333 | -18.475 | -15.737 |
Goodwill, Net | 47.806 | 47.806 | 47.806 | 47.806 | 47.806 |
Intangibles, Net | 124.076 | 126.747 | 128.845 | 131.502 | 142.548 |
Long Term Investments | 62.887 | 58.792 | 57.583 | 72.522 | 66.718 |
Other Long Term Assets, Total | 80.694 | 113.446 | 89.845 | 46.331 | 49.066 |
Total Current Liabilities | 110.239 | 118.905 | 89.591 | 118.32 | 106.052 |
Payable/Accrued | 17.432 | 21.025 | 17.569 | 14.828 | 9.319 |
Accrued Expenses | 11.923 | 9.812 | 7.66 | 12.037 | 28.084 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 80.884 | 88.068 | 64.362 | 91.455 | 68.649 |
Total Liabilities | 329.415 | 342.339 | 289.419 | 307.63 | 302.237 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Deferred Income Tax | 33.178 | 33.178 | 33.426 | 33.178 | 34.143 |
Other Liabilities, Total | 185.998 | 190.256 | 166.402 | 156.132 | 162.042 |
Total Equity | 1182.78 | 1194.83 | 1208.5 | 1233.28 | 1250.17 |
Common Stock | 747.914 | 744.756 | 742.816 | 734.365 | 730.427 |
Additional Paid-In Capital | 109.384 | 96.423 | 81.63 | 74.118 | 64.384 |
Retained Earnings (Accumulated Deficit) | 326.937 | 355.547 | 386.075 | 426.185 | 456.078 |
Total Liabilities & Shareholders’ Equity | 1512.19 | 1537.17 | 1497.92 | 1540.91 | 1552.41 |
Total Common Shares Outstanding | 289.778 | 289.189 | 288.427 | 286.852 | 285.762 |
Other Equity, Total | -1.46 | -1.899 | -2.021 | -1.391 | -0.717 |
Other Current Assets, Total | 25 | 25 | 25 | 25 | 71.499 |
Short Term Investments | 613.418 | 615.947 | 603.478 | 499.95 | 496.233 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 158.519 | 153.464 | 118.918 | -2.2107 | 0.30885 |
Cash From Operating Activities | 277.36 | 244.584 | 22.69 | 2.69372 | 3.56564 |
Cash From Operating Activities | 8.953 | 4.403 | 2.317 | 1.60408 | 0.91846 |
Non-Cash Items | 63.287 | 37.001 | 13.539 | 1.32723 | 0.42774 |
Changes in Working Capital | 29.825 | 41.672 | -116.701 | 1.9731 | 1.91059 |
Cash From Investing Activities | -352.625 | -332.247 | -119.78 | -5.77991 | -5.30707 |
Capital Expenditures | -72.66 | -58.452 | -14.673 | -3.99689 | -5.30707 |
Other Investing Cash Flow Items, Total | -279.965 | -273.795 | -105.107 | -1.78302 | 0 |
Cash From Financing Activities | -1.628 | -3.886 | 683.653 | 0.19483 | 12.1857 |
Issuance (Retirement) of Stock, Net | 2.755 | 4.615 | 598.502 | 0.01416 | 10.2056 |
Issuance (Retirement) of Debt, Net | -0.323 | -0.951 | 85.151 | 0.18067 | 1.98015 |
Net Change in Cash | -86.492 | -92.974 | 586.563 | -2.89137 | 10.4443 |
Amortization | 18.89 | 10.062 | 2.519 | ||
Deferred Taxes | -2.114 | -2.018 | 2.098 | ||
Financing Cash Flow Items | -4.06 | -7.55 | |||
Foreign Exchange Effects | -9.599 | -1.425 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -40.11 | 158.519 | 188.412 | 161.788 | 168.573 |
Cash From Operating Activities | -44.063 | 277.36 | 246.448 | 373.234 | 100.219 |
Cash From Operating Activities | 2.858 | 8.953 | 6.212 | 3.681 | 1.391 |
Amortization | 2.656 | 18.89 | 7.844 | 5.213 | 2.606 |
Deferred Taxes | -2.114 | ||||
Non-Cash Items | 13.446 | 63.287 | 43.148 | 26.226 | 12.675 |
Changes in Working Capital | -22.913 | 29.825 | 0.832 | 176.326 | -85.026 |
Cash From Investing Activities | -149.609 | -352.625 | -335.562 | -53.568 | -26.371 |
Capital Expenditures | -14.984 | -72.66 | -60.33 | -45.817 | -14.495 |
Other Investing Cash Flow Items, Total | -134.625 | -279.965 | -275.232 | -7.751 | -11.876 |
Cash From Financing Activities | -0.458 | -1.628 | -1.977 | -1.958 | -3.131 |
Financing Cash Flow Items | -0.948 | -4.06 | -4.06 | -4.06 | -5 |
Issuance (Retirement) of Stock, Net | 0.49 | 2.755 | 2.406 | 2.175 | 1.941 |
Issuance (Retirement) of Debt, Net | -0.323 | -0.323 | -0.073 | -0.072 | |
Foreign Exchange Effects | -0.213 | -9.599 | -9.963 | -1.411 | -0.204 |
Net Change in Cash | -194.343 | -86.492 | -101.054 | 316.297 | 70.513 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Thermopylae Holdings Ltd | Corporation | 19.3576 | 56012493 | 153000 | 2023-05-26 | LOW |
Baillie Gifford & Co. | Investment Advisor | 9.1115 | 26364751 | 6535100 | 2023-06-30 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 5.6851 | 16450180 | 6000000 | 2023-06-30 | LOW |
Thiel (Peter A. J.D.) | Individual Investor | 4.9629 | 14360427 | 0 | 2023-04-24 | LOW |
Voya Investment Management LLC | Investment Advisor/Hedge Fund | 3.6717 | 10624185 | -213840 | 2023-06-30 | LOW |
Lecault (Veronique) | Individual Investor | 3.2936 | 9530340 | 20000 | 2023-09-12 | LOW |
Capital World Investors | Investment Advisor | 2.9101 | 8420493 | -907000 | 2023-06-30 | LOW |
Credit Suisse Funds AG | Investment Advisor/Hedge Fund | 1.5809 | 4574523 | -33574 | 2023-06-30 | LOW |
Baillie Gifford Overseas Ltd. | Investment Advisor | 1.5726 | 4550522 | 0 | 2023-08-31 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.4449 | 4180768 | 0 | 2023-06-30 | LOW |
Founders Fund | Venture Capital | 1.4448 | 4180547 | 0 | 2023-06-30 | LOW |
ArrowMark Colorado Holdings, LLC | Investment Advisor/Hedge Fund | 1.4187 | 4105095 | 4105095 | 2023-06-30 | MED |
Lazard Asset Management, L.L.C. | Investment Advisor/Hedge Fund | 1.1319 | 3275301 | 32102 | 2023-06-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.1293 | 3267618 | 2060920 | 2023-06-30 | HIGH |
Federated Hermes International | Investment Advisor/Hedge Fund | 1.1246 | 3254000 | 446935 | 2023-06-30 | LOW |
Prosight Capital | Hedge Fund | 0.8813 | 2550000 | 1796472 | 2023-06-30 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 0.8766 | 2536603 | -274900 | 2023-06-30 | HIGH |
Casdin Capital, LLC | Hedge Fund | 0.8709 | 2520000 | 0 | 2023-06-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.7582 | 2193770 | 719890 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6975 | 2018226 | -9039634 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AbCellera Biologics Inc. Company profile
AbCellera Biologics Inc. (ABCL) is a Canadian biotechnology company that develops antibody discovery platforms. Its full-stack, AI-powered drug discovery platform searches and analyses the database of natural immune systems to find antibodies that can be used by its partners to develop into drugs.
ABCL was established in 2012 as a spin-off from the University of British Columbia (UBC), where Dr Carl Hansen, the company’s founding CEO, was a faculty member from 2005 to 2019.
The Vancouver-based company has collaborations with drug developers ranging from large cap pharmaceuticals to small biotechnology firms. As of the earnings date of 31 December 2021, the company had 156 discovery programmes either completed, in progress or under contract with 36 partners.
As a recent example, AbCellera Biologics teamed with pharma giant Eli Lilly (LLY) to co-develop two antibody therapeutics to treat and prevent Covid-19 utilising ABCL’s technological stack.
Some of the pharmaceutical companies that partnered with ABCL in the past two years include Everest Medicines for oncology or cancer; Kodiak Sciences (KOD) for partnership in eye care, Novarties (NVS), and Gilead Sciences (GILD) for infectious disease.
AbCellera Biologics was listed as a public company and began trading on the NASDAQ stock exchnage under the ticker symbol ‘ABCL’ in December 2020 through an initial public offering (IPO). ABCL’s stock price was set at $20.
You can follow the ups and downs of the ABCL’s stock price at Capital.com. Also, stay on top of the latest AbCellera Biologics’ stock price developments with our live ABCL stock chart.
Industry: | Biotechnology & Medical Research (NEC) |
2215 Yukon Street
VANCOUVER
BRITISH COLUMBIA V5Y 0A1
CA
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com